Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
28.8M
-
Shares change
-
+2.36M
-
Total reported value, excl. options
-
$787M
-
Value change
-
+$69.1M
-
Put/Call ratio
-
0.65
-
Number of buys
-
92
-
Number of sells
-
-38
-
Price
-
$27.36
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2018
173 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2018.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.8M shares
of 108M outstanding shares and own 26.68% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (4.51M shares), STATE STREET CORP (2.7M shares), BlackRock Inc. (2.56M shares), FMR LLC (2.53M shares), VANGUARD GROUP INC (2.37M shares), MORGAN STANLEY (2.23M shares), Atlas Venture Associates IX, LLC (1.84M shares), ORBIMED ADVISORS LLC (876K shares), FARALLON CAPITAL MANAGEMENT LLC (840K shares), and Temasek Holdings (Private) Ltd (791K shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.